Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dasotraline - Sumitomo Dainippon Pharma

Drug Profile

Dasotraline - Sumitomo Dainippon Pharma

Alternative Names: DSP-225289; SEP 225289; SEP-0225289; SEP-225289-HCI; SEP-289

Latest Information Update: 07 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sepracor
  • Developer Sepracor; Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals
  • Class Amines; Antidepressants; Cyclobutanes; Naphthalenes; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Attention-deficit hyperactivity disorder; Binge-eating disorder
  • Discontinued Major depressive disorder

Most Recent Events

  • 30 Jul 2019 FDA assigns PDUFA action date of (14/04/2020) for dasotraline for Binge-eating disorder
  • 30 Jul 2019 Sunovion Pharmaceuticals announces intention to submit sNDA to US FDA for Eating disorders in fiscal year 2018
  • 30 Jul 2019 The US FDA accepts NDA for Binge-eating disorder for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top